Abstract
Objectives
The aim of this study was to evaluate the longterm follow-up results of percutaneous transluminal septal myocardial ablation (PTSMA) in a large patient cohort.
Background
PTSMA by alcohol injection into septal branches has shown good acute and short-term results in symptomatic patients with hypertrophic obstructive cardiomyopathy.
Methods
A total of 100 consecutive symptomatic (NYHA class 2.8 ± 0.6) patients underwent PTSMA. All patients had clinical and non-invasive follow-up at 3 months, 1 year, and annually up to 8 years.
Results
One patient died at day 2 after intervention due to fulminant pulmonary embolism following deep venous thrombosis, and eight patients required a permanent DDD-pacemaker due to post-interventional complete heart block. Acute reduction of the left ventricular outflow tract gradient was achieved from 76 ± 37 to 19 ± 21 mmHg at rest, from 104 ± 34 to 43 ± 31 mmHg during Valsalva maneuver, and from 146 ± 45 to 59 ± 42 mmHg post extrasystole (p < 0.0001, each). During follow-up (mean follow-up time: 58 ± 14 months), three additional patients died (sudden death at 48 months, non-cardiac death at 49 months and stroke-related death at 60 months after the index procedure). All living patients showed clinical improvement to NYHA-class 1.4 ± 0.6 (after 3 months, n = 99), 1.5 ± 0.6 (after 1 year, n = 99), and 1.6 ± 0.7 at final follow-up (n = 96; p < 0.0001, each). Non-invasive follow-up studies documented ongoing outflow tract gradient reduction, decrease of septal and left ventricular posterior wall thickness, and improvement of exercise capacity.
Conclusions
PTSMA is an effective treatment for symptomatic patients with hypertrophic obstructive cardiomyopathy. Follow-up showed ongoing hemodynamic and clinical improvement without increased mortality and morbidity.
Similar content being viewed by others
References
Wigle ED, Rakowski H, Kimball BP, Williams WG (1995) Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation 92:1680– 1692
Maron BJ, McKenna WJ, Danielson GK et al (2003) American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 42:1687–1713
Spirito P, Seidman CE, McKenna WJ, Maron BJ (1997) The management of hypertrophic cardiomyopathy. N Engl J Med 336:775–785
Schoendube FA, Klues HG, Reith S, Flachskampf FA, Hanrath P, Messmer BJ (1995) Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus. Circulation 92:II122–127
Schulte HD, Gramsch-Zabel H, Schwartzkopff B (1995) Hypertrophe obstruktive Kardiomyopathie: Chirurgische Behandlung. Hypertrophic obstructive cardiomyopathy: surgical treatment. Schweiz Med Wochenschr 125:1940–1949
Heric B, Lytle BW, Miller DP, Rosenkranz ER, Lever HM, Cosgrove DM (1995) Surgical management of hypertrophic obstructive cardiomyopathy. Early and late results. J Thorac Cardiovasc Surg 110:195–206 (discussion 206–208)
Woo A, Williams WG, Choi R et al (2005) Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation 111:2033–2041
Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS (1999) Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation 99:2927–2933
Sigwart U (1995) Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 346:211–214
Gleichmann U, Seggewiss H, Faber L, Fassbender D, Schmidt HK, Strick S (1996) Kathetertherapie der hypertrophen obstruktiven Kardiomyopathie. Catheter treatment of hypertrophic obstructive cardiomyopathy. Dtsch Med Wochenschr 121:679–685
Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S (1998) Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol 31:252–258
Faber L, Seggewiss H, Gleichmann U (1998) Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation 98:2415–2421
Knight C, Kurbaan AS, Seggewiss H et al (1997) Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. Circulation 95:2075–2081
Nagueh SF, Lakkis NM, He ZX et al (1998) Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 32:225–229
Gietzen FH, Leuner CJ, Raute-Kreinsen U et al (1999) Acute and longterm results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 20:1342–1354
Sahn D, De Maria A, Kisslo J, Weyman A (1978) Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. The committee on M-mode standardization of the American Society of Echocardiography. Circulation 58:1072–1083
Pollick C, Rakowski H, Wigle ED (1984) Muscular subaortic stenosis: the quantitative relationship between systolic anterior motion and the pressure gradient. Circulation 69:43–49
Seggewiss H (2001) Current status of alcohol septal ablation for patients with hypertrophic cardiomyopathy. Curr Cardiol Rep 3:160–166
Elliott PM, Poloniecki J, Dickie S et al (2000) Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 36:2212–2218
Qin JX, Shiota T, Lever HM et al (2001) Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol 38:1994–2000
Firoozi S, Elliott PM, Sharma S et al (2002) Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy. A comparison of clinical, haemodynamic and exercise outcomes. Eur Heart J 23:1617–1624
Lakkis NM, Nagueh SF, Dunn JK, Killip D, Spencer WH 3rd (2000) Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up. J Am Coll Cardiol 36:852–855
Faber L, Meissner A, Ziemssen P, Seggewiss H (2000) Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients. Heart 83:326–331
Schulz-Menger J, Strohm O, Waigand J, Uhlich F, Dietz R, Friedrich MG (2000) The value of magnetic resonance imaging of the left ventricular outflow tract in patients with hypertrophic obstructive cardiomyopathy after septal artery embolization. Circulation 101:1764–1766
Curtius JM, Stoecker J, Loesse B, Welslau R, Scholz D (1989) Changes of the degree of hypertrophy in hypertrophic obstructive cardiomyopathy under medical and surgical treatment. Cardiology 76:255–263
Rivera S, Sitges M, Azqueta M et al (2003) Left ventricular remodeling in patients with hypertrophic obstructive cardiomyopathy treated with percutaneous alcohol septal ablation: an echocardiographic study. Rev Esp Cardiol 56:1174–1181
Maron BJ (1999) New interventions for obstructive hypertrophic cardiomyopathy: promise and prudence. Eur Heart J 20:1292–1294
Frenneaux MP, Counihan PJ, Caforio AL, Chikamori T, McKenna WJ (1990) Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. Circulation 82:1995–2002
Raute-Kreinsen U (2003) Morphology of necrosis and repair after transcoronary ethanol ablation of septal hypertrophy. Pathol Res Pract 199:121–127
Maron MS, Olivotto I, Betocchi S et al (2003) Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 348:295–303
Faber L, Welge D, Fassbender D, Schmidt HK, Horstkotte D, Seggewiss H (2007) One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of haemodynamic and clinical response. Clin Res Cardiol (in press)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Seggewiss, H., Rigopoulos, A., Welge, D. et al. Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Clin Res Cardiol 96, 856–863 (2007). https://doi.org/10.1007/s00392-007-0579-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00392-007-0579-8